Skip to main content
a2 Milk flags weaker first half, China at 50% recovery
Image for illustrative purposes only. Not a real photo.

a2 Milk flags weaker first half, China at 50% recovery

By

Key points

  • The a2 Milk Company expects first-half FY27 earnings to be materially lower than a year earlier, as its China infant formula sales recover.
  • a2 Milk shares were down at $6.58, from a $6.78 open.
  • The company said revenue and earnings will be heavily weighted to the second half, helped by new products and more marketing.

The a2 Milk Company (ASX:A2M) expects first-half FY27 earnings to be materially lower than a year earlier, as sales of its China infant formula recover from supply shortfalls.

The company said sales of its China label formula have recovered to about 50% of their levels before the disruption, up from about 40% in August 2026.

a2 Milk expects total infant formula sales in FY27 to be broadly similar to FY26, with revenue and earnings materially weighted to the second half.

For FY27, the company expects mid-single-digit revenue growth, with first-half revenue slightly down, and an underlying EBITDA margin of about 15%.

a2 Milk said the recovery will be supported by two new China label products, an updated a2 Platinum product and higher marketing spending, particularly in the first half.

Following the announcement the a2 Milk share price was down at $6.58.

The company expects about $15 million in one-off transformation costs in FY27, linked to its Pōkeno plant in New Zealand and the a2 Platinum transition, with none expected in FY28.

The setback followed shortages of China label formula in the June quarter of 2026, and a recall of a small volume of US-label a2 Platinum formula in May 2026.


Frequently asked questions